D. Valentinuzzi, “[18F]FDG PET immunotherapy radiomics signature (iRADIOMICS) predicts response of non-small-cell lung cancer patients treated with pembrolizumab”, Radiol Oncol, vol. 54, no. 3, pp. 285–294, Sep. 2020.